USA's Top-Selling Drugs In 1993
According to the trade journal Med Ad News, the USA's 10 best-selling prescription drugs in 1993 were:
- Glaxo's Zantac (ranitidine), $1.9 billion; - Pfizer's Procardia (nifedipine), $1.2 billion; - Merck's Mevacor (lovastatin), $1.1 billion; - Merck's Vasotec (enalapril), $895 million; - Lilly's Prozac (fluoxetine), $875 million; - Marion Merrell Dow's Cardizem (diltiazem), $797 million; - SmithKline Beecham's Tagamet (cimetidine), $648 million; - Wyeth-Ayerst's Premarin (conjugated estrogens), $644.2 million; - Miles' Cipro (ciprofloxacin), $613.9 million; and - Amgen's Epogen (erythropoietin), $586.9 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze